Stivarga Regulatory Post-Marketing Surveillance Study in Korea

* Inclusion Criteria: * Signed and dated informed consent * Patients diagnosed with histologically confirmed metastatic colorectal cancer and/or metastatic or unresectable locally advanced gastrointestinal stromal tumors and/or HCC who have been previously treated with sorafenib by physician * Patients who are prescribed with Stivarga tablet 40mg(Regorafenib) for the first time * Exclusion Criteria: * Patients participating in an investigational program with interventions outside of routine clinical practice * All contra-indications according to the local marketing authorization have to be considered.